Protalix BioTherapeutics (PLX)
Develops and manufactures plant-cell-derived enzyme therapies for rare diseases.
Something off on this page? Send us feedback.
Develops and manufactures plant-cell-derived recombinant protein therapies for Gaucher and Fabry diseases, earning product-supply and milestone revenue through commercialization partners. Its integrated model combines a proprietary expression platform and Israeli production site with partner-controlled global distribution.
Develops recombinant protein therapies for rare diseases through ProCellEx, a plant-cell suspension expression platform. Approved enzyme-replacement products include Elelyso for Gaucher disease and Elfabrio for Fabry disease, while PRX-115 is in clinical development for uncontrolled gout.
Manufactures commercial drug substance and clinical material at its Carmiel, Israel facility, pairing in-house discovery and production with partner-led commercialization. Pfizer markets Elelyso outside Brazil, Chiesi commercializes Elfabrio globally, and Fiocruz distributes the Brazilian taliglucerase alfa presentation.
Revenue comes chiefly from product deliveries and milestones under these collaborations and is recognized when inventory reaches partners rather than when patients use it. Operations depend on a single Israeli manufacturing site, continued product approvals, partners' commercial execution, and pipeline progress.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 13, 2026 | Raymond James | Initiate | Rating: —Target: — | Target: $6 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $40.7M · Total debt $9.2M · Total assets $110.3M · Shareholders' equity $71.4M
- Revenue
- $52.7M
- Operating income
- −$5.5M
- Net income
- −$6.6M
No dividends on record.
| Institutions | ≈ 18.18% | 14.65M shares | |
|---|---|---|---|
| 109 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Other | ≈ 81.82% | 65.92M shares | |
| remainder | |||
80.57M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 5.02% | 4.05M | as of Jun 30, 2026 |
Renaissance Technologies LLCInstitution | 1.36% | 1.10M | as of Jun 30, 2026 |
State Street CorpInstitution | 1.22% | 983,582 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 1.22% | 979,995 | as of Jun 30, 2026 |
Northern Trust CorpInstitution | 1.14% | 922,340 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Sanofi (ADR)
Broad established rival across Gaucher and Fabry disease therapy.
- Takeda (ADR)
Dual enzyme-replacement rival in Gaucher and Fabry disease.
- Amgen
Approved uricase benchmark for uncontrolled gout.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Protalix BioTherapeutics | $2.83 | +2.54% | $221.6M | 11.9 | — | 2.7 | +27.1% |
| Sanofi (ADR) | $42.46 | −0.09% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| Takeda (ADR) | $18.99 | +0.50% | $60.11B | 52.5 | 60.0 | 2.0 | +4.2% |
| Amgen | $407.31 | +3.60% | $212.19B | 24.4 | 17.4 | 5.6 | +9.7% |
| Median | 52.5 | 38.7 | 2.0 | +9.7% |